Alignment Healthcare, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Alignment operates Medicare Advantage plans across six states and reported 165,100 health plan members in 53 markets at quarter-end.
Key financial results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $628.6 million | $439.2 million | +43.1% |
| Earned premiums | $621.6 million | $434.8 million | +42.9% |
| Medical expenses | $573.2 million | $396.3 million | +44.6% |
| Medical benefits ratio (MBR) | 90.9% | 89.7% | +1.2 percentage points |
| SG&A expenses | $90.5 million | $70.4 million | +28.6% |
| Operating loss | $41.1 million | $32.5 million | Loss increased |
| Net loss | $46.6 million | $37.4 million | Loss increased 24.6% |
| Net loss per diluted share | $0.25 | $0.20 | Loss per share increased |
| Adjusted gross profit | $57.3 million | $45.4 million | +26.2% |
| Adjusted EBITDA | $(12.0) million | $(5.2) million | Loss widened |
| Operating cash flow | $(6.2) million | $85.1 million | Decreased $91.3 million |
Liquidity, debt and balance sheet
- At March 31, 2024, cash and cash equivalents were $238.9 million, current investments were $62.8 million, and cash, cash equivalents and short-term investments totaled $301.7 million. Cash, cash equivalents and restricted cash were $241.1 million.
- Total assets were $633.2 million and total liabilities were $501.2 million. Medical expenses payable rose to $276.5 million from $205.4 million at year-end 2023.
- Long-term debt had $165.0 million principal outstanding and a $162.0 million net carrying value. The floating interest rate ranged from 11.82% to 11.85% in the quarter; principal is due September 2027. The company was in compliance with loan covenants, including a $23.0 million minimum-liquidity requirement.
Material changes and drivers
- Health plan membership increased 50.5% year over year, driving premium growth. Medical costs grew faster than earned premiums, reflecting a higher share of new members, richer benefits, higher unit costs and less favorable prior-year development; lower inpatient admissions per thousand partly offset these pressures.
- Q1 2024 MBR increased to 90.9% from 89.7%. Management notes that new members typically have higher MBRs and that results vary with member mix and seasonality.
- ACO REACH revenue treatment changed from gross to net beginning in 2024 following a third-party risk-management arrangement. ACO revenue recognized in Q1 2024 was $1.0 million versus $32.1 million in Q1 2023; the change also affects comparability of medical expenses and revenue.
- SG&A growth reflected investment in network development, operations, sales and marketing. Q1 2024 included $1.8 million of restructuring costs in the company’s Adjusted EBITDA reconciliation, $0.8 million of which related to medical expenses.
- Operating cash flow comparison was affected by timing: Q1 2023 included $141.1 million of deferred premium revenue because April CMS premiums were received in March. Excluding that deferred premium revenue, the company said operating cash flow decreased by $49.5 million year over year.
Outlook, risks and contingencies
- No specific revenue, earnings or membership guidance for 2024 is provided in the filing. Management believes liquid assets are sufficient for operating and organic capital needs for at least the next 12 months, but cautions that growth, spending, acquisitions and other factors could increase capital needs and that additional financing may not be available on acceptable terms.
- Management expects continued investment in technology, market expansion, sales and marketing, and public-company costs. It describes seasonal patterns: member growth is concentrated in Q1; medical costs are generally higher in Q1 and Q4; and Part D costs tend to be higher in the first half.
- Key risks include medical-cost and incurred-but-not-reported claims estimation, risk-adjustment data accuracy and government review, CMS reimbursement and regulation, maintaining plan Star ratings and provider relationships, growth execution, cybersecurity, and the company’s history of losses. More than 90% of members were enrolled in plans rated four stars or higher; CMS Star ratings affect financial performance with a lag.
- Regulated health plans and risk-bearing entities met applicable minimum capital requirements. Transfers from regulated subsidiaries may be restricted or require regulatory approval.
- A tentative $0.9 million settlement of a former employee meal-and-rest-break class action was accrued; court approval was expected in Q3 2024. Management does not expect other ordinary-course legal matters to have a material adverse effect.
- After quarter-end, on April 30, 2024, the company amended its stockholders agreement, removing certain board committee appointment and approval rights held by lead stockholders, including specified transaction and CEO-related approval rights.
Important facts for investors to verify
- Whether membership growth can be sustained while improving MBR and controlling medical-cost growth.
- How much of reported revenue and expense comparability reflects the ACO REACH gross-to-net accounting change.
- Development of medical expenses payable and the adequacy of claims reserves as actual claims emerge.
- Cash generation excluding premium-receipt timing effects, and whether liquidity remains adequate under growth and investment plans.
- Floating-rate debt costs, covenant headroom, and the ability to fund obligations due in 2027.
- Progress and final court approval of the accrued class-action settlement, and the effects of the amended stockholders agreement.